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The a(2 -).8)-linked N-acetyl neuraminic acid (NeuNAc) polymer has unique
properties that distinguish it from other bacterial capsular polysaccharides
(CPS).' It is the major virulence factor of two human pathogens, the group B
meningococcus, and Escherichia coli K1 (1, 2) . However, unlike almost all other
capsular polysaccharides, this polymer, either purified oron formalin-inactivated
whole bacteria, is either nonimmunogenic or elicits low levels of antibodies in a
small proportion of recipients (3) . Moreover, it is susceptible to rapid hydrolysis
bya mammalian enzyme, neuraminidase, resulting in degradation of the antigen .
The a(2 -* 8) glycosidic linkage of this polysaccharide is identical to that of the
terminal NeuNAc residues of gangliosides and some neural glycoproteins (4, 5) .
The poor immunogenicity of this polysaccharide, therefore, has been explained
by the structural similarity of this antigen with the host's tissues .
Individuals whose serum electrophoresis patterns showed monoclonal peaks
were screened with our collection of polysaccharides (6, 7) . We have found an
81-yr-old man (NOV) whose monoclonal IgM antibody showed a precipitin line
by the Ouchterlony method with both group B meningococcal and E. coli K1
capsular polysaccharides . Quantitative precipitin curves showed specificity for
a(2 --* 8)-linked poly-N-acetylneuraminic acid ; no precipitin reactions were
obtained with a(2 --* 9)-linked poly-N-acetylneuraminic acid, the CPS of the
group C meningococcus, nor with the CPS ofE . coli K92 or K100 . An 0-acetyl-
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' Abbreviation used in this paper :
￿
CPS, capsular polysaccharide.
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containing E . coli K1 preparation showed very low reactivity . Colominic acid,
also a(2 --+ 8)-linked NeuNAc (8), precipitated only slightly due to its low
molecular mass .
In this report we show that (a) this antibody, which was present in the serum
at a concentration of 23 mg/ml, is protective against E. coli in newborn rats, (b)
the antibody specificity is of especial interest, in that it crossreacts with polynu-
cleotides and denatured DNA, but has not caused any signs and symptoms of
disease, and (c) relevant B cells derived from the patient could be infected with
EBV and grown in culture .
Materials and Methods
Case Description .
￿
NOV is an 81-yr-old white male who was found, during treatment
(October 1984) for anemia and rectal bleeding to have an IgM X monoclonal gammopathy .
A carcinoma of the rectosigmoid (Dukes B) was found, and resection and end-to-end
anastomosis was performed . Past medical history included probable rheumatic fever and
rheumatic heart disease necessitating a Bjork-Shiley aortic valve replacement in 1971, and
prostatectomy in 1975 for benign prostatic hypertrophy .
Aside from a persistent low-grade anemia (hemoglobin in the range of 10-12 g/dl),
there have been no signs or symptoms referable to macroglobulinemia (i.e ., no lymphad-
enopathy or hepatosplenomegaly, no hyperviscosity or vascular abnormalities) . He has no
history of protracted infections, although the bowel cancer, which was ulcerated, could
possibly have been a portal of entry for enteric bacteria . We have seen no signs or
symptoms ofSLE or any neurologic manifestations, which might reflect untoward effects
of the antibody in vivo .
Sera .
￿
Serum IgM"° `' was available . Other human monoclonal IV-containing sera
were IgMr's (7), which reacted with chondroitin sulfates A, B, C ; IgM
En
(6) ; IgM" Y (6),
reacting with Klebsiella polysaccharides containing 3,4-pyruvylated galactose ; IgM"° ;
and IgMco", both with unknown specificity, served as controls in ELISA .
Polysaccharides and Polynucleotides.
￿
We used two preparations of meningococcal CPS
group B, one from Dr . Carlos Moreno (Wellcome Research Laboratories, Beckenham,
Kent, United Kingdom) (9) . The following polysaccharides and polynucleotides were also
available : meningococcal groups C and Y ; E. coli K1, CPS strains 016 and K235 (0-acetyl-
negative) ; and the 0-acetyl-positive and 0-acetyl-negative form variants of strain LH
(10) ; E . coli K92, strains N67 and MT1389 ; E. coli K100 ; dextrans N-279, B-1299S, B-
1355S, and N-150-N ; levan B512E and P-6 ; phosphomannan ; inulin ; also blood group
substances: Beach phenol insoluble P1, Tij II 20% from second 10%, Lea substance N-1
first 104 , hog mucin blood group A and H substance . We also used arabinogalactan ;
Arianta arbustorum galactan, Helix pomatia galactan ; Helix nemoralis galactan, pneumococ-
cal CPS types IV, VIII, XIV, and XXVII ; Rhizobium TA, ; Klebsiella K7, K1, K30, and
Hemophilus influenzae CPS types a, b, c, d, e and f; poly(dihydro U), poly(U), poly(A),
poly(G), poly(C), poly(I), poly(dAdT) 2 , poly(dT)4 ; chondroitin sulfates A, B, and C (6, 7) .
Denatured calf thymus DNA (Worthington Biochemical Corp ., Freehold, NJ) was pre-
pared by boiling for 15 min and cooling rapidly .
Equine Group B Meningococcal Antiserum .
￿
The antiserum (H46) was from bleedings of
a horse injected intravenously with formalin-inactivated group B meningococcal strain B-
11 as described (11) . The isotype of the precipitating antibody to the group B meningo-
coccal CPS in this antiserum is IgM ; the sample used for protection tests contained 1 .25
mg of antibody per milliliter of serum, as determined by quantitative precipitin analysis .
Protection Tests .
￿
5-d-old Sprague-Dawley rats (Taconic Farms, Inc ., Germantown, NY)
were challenged with an i.p . injection of various doses ofE. coli 018:K1 :H7 (strain C64),
observed for 72 h, and the LD5 was determined (12-14) . Antisera were assayed for their
protective properties by i.p . injection of 50 tal of serum dilutions 4 h before challenge
with one LD5 or multiples of LD5(, doses . Tail vein blood samples of 10-20 A1 were plated644 HUMAN MONOCLONAL ANTI-GROUP B MENINGOCOCCAL ANTIBODY
at 24 h, and colonies were counted. Results list survival times only, because, ofthe animals
that had positive blood cultures, only two survived.
Gel Diffusion.
￿
The Ouchterlony technique was used (15). Gels consisted of 13.0 ml of
I % agarose in saline containing 0 .05% sodium azide, on an 8.3 x 10.2-cm glass plate. Six
wells were distributed hexagonally 6 mm from a central well; 5 A,1 ofantiserum and various
polysaccharides, DNA, or polynucleotides were added. Plates were developed in a chamber
containing moist filter paper.
Quantitative Precipitin Curves.
￿
To 15 jI of a 1 :10 dilution of IgM"°", or 100 A1 of a
1 :5 dilution of H46, increasing amounts of various polysaccharides, polynucleotides, or
native or denatured DNA were added in amounts of 0.2-43 tug in a total volume of 200
Fcl (16). After 1 h at 37°C and 1 wk in the refrigerator (with mixing twice daily), the tubes
were centrifuged at 2,000 rpm for 1 h, and washed twice in the cold with 500 jl of saline.
The precipitates were then digested with 25 Al of a 1 :20 dilution of concentrated H2S04,
15 al of 30% H202 were added, the precipitates were redigested, then analyzed for
nitrogen by the ninhydrin method (17) . The serum blank and the supernatant from the
tube in which maximum precipitation was found were examined by cellulose acetate
electrophoresis.
ELISA for Antimeningococcal Antibody.
￿
A Corning 96-well round-bottom plate was
coated with 100,uI of 10-5 dilutions of H46 antimeningococcal group B globulin in borate-
buffered saline (BBS), pH 8 .0. The plate was incubated at 37°C for 1 h, the solution
removed, and the wells washed twice with 0.05% Tween 20 in PBS. Unreacted sites were
blocked with 200 jl of 1 % BSA in PBS for 1 h at room temperature, and the plate was
again washed twice with PBS-Tween. 100 y1 of 10 jug/ml meningococcal group B CPS
were added, and the plate was incubated at 37°C for 2 h, washed twice, and 100 11 of B
cell culture supernatant or serum-containing antibody were added and incubated for 2 h
at 37°C or overnight at 4° C. The plate was washed two or three times with PBS-Tween
20. 100 A1 of a 1 :2,000 dilution of alkaline phosphatase-conjugated goat anti-human
IgM were added, the plate was kept at 37°C for 2 h, washed four times with PBS-Tween
20, and 0.1 ml of substrate containing 6 mg of p-nitrophenylphosphate in 10 ml of
diethanolamine buffer, pH 9.8, were added. After 1 h at room temperature, the reaction
was stopped by adding one drop of 3 N NaOH, and the plate was read at 410 nM .
ELISAfor Anti-DNA Antibody.
￿
Sera, immunoglobulin fractions, and supernatants from
the B cell line and its clones were tested for anti-DNA activity using an ELISA similar to
that described by Shoenfeld et al. (18). The inner 60 wells of Costar EIA 96-well plates
were coated with poly-L-lysine (50 tag/ml; Sigma Chemical Co., St. Louis, MO), and
incubated for 2 h. After washing with PBS, native or denatured calf thymus DNA (5
tag/ml; Worthington Biochemical Corp.) was added to half of the wells, distilled water to
the other half, and the plates were incubated at room temperature for 1 h . The plates
were washed again and coated with poly-L-glutamate, 50 fag/ml, for 1 h . The plates were
washed and could be stored at this stage for several days at 4°C. Sera or supernatants
were then added in duplicate to the DNA-coated wells and control wells, and incubated
1 h. The wells were washed thoroughly with PBS-Tween, (Kirkegaard and Perry Labo-
ratories, Inc., Gaithersberg, MD), aspirated dry, and alkaline phosphatase-conjugated
goat anti-human IgM (Kirkegaard and Perry Laboratories, Inc.) was added at a 1 :2,500
dilution. The plates were incubated overnight. The plates were again thoroughly washed,
aspirated dry, and p-nitrophenylphosphate (1 mg/ml in diethanolamine buffer) was added
to each well . The reaction was stopped with 5 N NaOH, and optical densities were read
at 405 nm on a Bio-Tek (model EL307EIA; Bio-Tek Instruments, Inc ., Burlington, VT)
reader.
EBV-transformed B CellLine and Clones.
￿
Peripheral blood lymphocytes from the patient
were harvested after Ficoll-diatrazoate gradient centrifugation, rosetted with sheep eryth-
rocytes, and the nonrosetted fraction was further depleted of T cells by treatment with
anti-T3, anti-T11, and rabbit complement (19). This B cell-enriched population was then
infected with EBV obtained from the supernatant of B95-8 marmoset leukocytes (Amer-
ican Type Culture Collection, Rockville, MD) incubated at 37°C with 5% C02, and fed
twice weekly with Iscove's modified Dulbecco's medium (IMDM; Life Technologies, Inc.,0
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Results
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FIGURE 1.
￿
Quantitative precipitin curves for IgM"ov with various polysaccharides, polynu-
cleotides, and DNA. 15 Al of a 1 :10 dilution of IgM"ov in a total volume of 200 All. (A) Total
nitrogen precipitated. (B) Antibody nitrogen precipitated. G, meningococcal CPS group B; ",
E. coli K1 CPS LH 0-acetyl-negative; O, E. coli K1 CPS 016 0-acetyl-negative; 0, poly(A); ®,
poly(I); ", E. coli K235 CPS 0-acetyl-negative; C, denatured DNA; *, poly(G); m, colominic
acid; V, Bacto-agar, 20°C, extracted; 0, E. coli K1 CPS LH 0-acetyl-positive; A, E. coli K100
CPS; A, E. coli K92 CPS N67; A, E. coli K92 CPS MT1389; 10, meningococcal CPS group C;
11, meningococcal CPS group Y; G, native DNA; G, chondroitin sulfate type A; m, chondroitin
sulfate type B; A, chondroitin sulfate type C; ®, Klebsiella K21 ; ®, Klebsiella K30 ; O,
polysialoglycoprotein.
Chagrin Falls, OH) containing 5% FCS (HyClone Laboratories, Logan, UT). After 3 wk,
the cells were transferred to a flask and cloned by limiting dilution into 96-well microtiter
plates (Costar, Cambridge, MA) in medium consisting of a 2:1 mixture of IMDM, and B
cell-conditioned medium with 10% FCS. The B cell-conditioned medium was obtained
by filtering the supernatant from an EBV-immortalized B cell line derived from a normal
healthy donor. After 2-3 wk, supernatants from clones were assayed for anti-DNA activity
while still growing in microtiter plates. Thereafter, they were transferred to 24-well and
then to 12-well plates and assayed repeatedly for anti-DNA and antimeningococcal activity.
Phenotypic Analysis by Direct and Indirect Immunofuorescence of NOV B Cell Line.
Phenotypic analysis of the B cell line was performed by indirect immunofluorescence with
the mAbs OKB4 and OKIa, the monocyte markers, OKM I and OKM2, and the T cell
marker, OKT3, and fluorescein-conjugated affinity-purified F(ab')2 goat anti-mouse IgG
+ IgM (The Jackson Laboratories, Bar Harbor, ME) using a model 30-H Cytofluorograph
(Ortho Diagnostic Systems, Inc., Raritan, NJ) as described (19). Direct immunofluores-
cence was done using fluorescein F(ab')2 fragments of goat anti-human x and anti-
human X (free and bound light chain-specific), as well as with fluorescein-conjugated
rabbit and human Ig. Fluorescein conjugates were added to 5 x 105 cells at appropriate
dilutions, mixed and incubated at 4°C for 30 min. The cells were washed twice and
resuspended in PBS with 0.1 % sodium azide. Fluorescein-conjugated OKT3 was included
as a control.
Quantitative Precipitin Studies.
￿
Screening by the Ouchterlony method showed
that IgMNov
reacts with E. coli K1 and group B meningococcal CPS. We then
set up quantitative precipitin curves (Fig. 1). The two preparations of group B
meningococcal CPS and the two E. coli K1 CPS from the 0-acetyl-negative646 HUMAN MONOCLONAL ANTI-GROUP B MENINGOCOCCAL ANTIBODY
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FIGURE 2.
￿
Quantitative precipitin curves for H46 with various polysaccharides, polynucleo-
tides, and DNA. Symbols as in Fig. 1 . 100 juI 1 :5-diluted anti-horse 46 total volume: 200 jl.
variants of strain LH and 016 gave identical precipitin curves over a range of 2-
7 wg nitrogen with these CPS. A maximum of ^-5.6 )ug nitrogen was precipitated
from 15 jl of a 1 :10 dilution of the patient's serum. This is equivalent to 23 mg
of antibody per milliliter. E. coli CPS K235 (0-acetyl-negative) was --40 percent
as effective per unit weight in precipitating K1 antibodies from this serum,
probably due to lower molecular mass; colominic acid reacted only slightly; the
O-acetylated E. coli K1 strain LH gave only minimal precipitation ; and there was
no precipitation with K92, strains N67 and MT 1389, nor with K 100.
The high degree of specificity for a(2 --+ 8)-linked poly-NeuNAc of which the
E. coli KI and meningococcal group B CPS are composed is seen by the absence
of precipitation over a wide range of concentrations of other polysaccharides,
including meningococcal group C, a(2 --> 9)-linked poly-NeuNAc; E. coli K92,
built of alternatinga(2 --)- 8)a(2 --* 9)-linked NeuNAc; with meningococcal group
Y (NeuNAc-a(2 -> 4)Glc-a(I ----> 6)NeuNAc); and by the lower activity of the E.
coli K1 0-acetyl-positive variant of strain LH (for elucidation of structures see
Egan [20]). IgMN°v also reacted with polynucleotides, poly(A) and poly(I) being
as active as the two group B meningococcal and E,. coli K1 CPS. Although native
DNA did not precipitate, denatured DNA gave a good precipitin curve, as did
poly(G). With denatured DNA or poly(G), more total nitrogen was precipitated
than the maximum found far meningococcal group B and E. coli KI polysaccha-
rides (Fig. 1 A), this was due to the higher nitrogen content of DNA and the
polynucleotides. Fig. 1 B shows that when the nitrogen content of the added
antigens was subtracted, and antibody nitrogen precipitated was plotted against
antigen added, both curves reached the same maximum; this did not occur with
poly(A) and poly(l), perhaps due to slightly higher solubility of their antigen-
antibody complexes. The denatured DNA was only 33% as effective per unit
weight in precipitating IgMN°", and poly(A), and poly(l) were about as active
(within experimental error) as the most active CPS.
Quantitative precipitin studies on H46 (Fig. 2) showed that group B menin-TABLE I
Antibody IgM'VOV Protects Infant Rats against Escherichia coli KI Infection
KABAT ET AL .
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gococcal polysaccharide and E. coli K1 CPS from the 0-acetyl-negative variant
of strains LH and 016 give identical precipitin curves . The 0-acetyl-negative
CPS, K235 and K92 were poorer ; meningococcal group C CPS gave a minimal
reaction ; E . coli K100 and meningococcal group Y CPS gave no or barely
detectable precipitation. Poly(A), poly(I), and native and denatured DNA did
not react . Poly(G) reacted, but ^-16 times more poly(G) was needed than with E.
coli K1 and groupB meningococcal CPS .A variety ofother structurally unrelated
polysaccharides did not react .
Protective Power ofIgM"'°°.
￿
Assays of the protective power of a serum sample
containing IgMNOV taken September 26, 1984, and of the H46 antiserum are
summarized in Table 1 . The LD5o was 5-15 CFU/animal . 1 Ag of antibody (50
A1 of 1:1,165 dilution), as well as 1 mg of H46 protected all infant rats against
challenge with 33 LD5o ofE. coli K1 .
Anti-DNA Binding ofSerum Samples and Immunoglobulin Fractions ofIgM" .
Serum ofIgMNov showed specific binding with both denatured and nativeDNA
in ELISA (Fig . 3), but the latter was less active per unit weight . In comparable
inhibition ELISA, it was ---1,000 times less active than denatured DNA at
inhibiting binding to denatured DNA or to group B meningococcal CPS (data
not shown) . Purified IgM fractionswere also similarlypositive forboth denatured
and native DNA (Fig . 3D) . To test whether this anti-DNA activity was due to
the antimeningococcal mAb, serum was absorbed with meningococcal polysac-
charide and retested . These supernatants lost reactivity with both denatured
DNA and meningococcal polysaccharide (Fig . 3C) .
To exclude nonspecific binding of IgM antibodies to denatured DNA as a
possible explanation of our observations, serum from five other patients with
macroglobulinemia were tested in parallel with serum NOV (Fig . 3, A and B) .
At lowconcentrations, some of these five sera bound nonspecifically to the plates,
Protective activity of antisera
Exp . LD5o (E. coli
CFU/rat) Challenge dose Antiserum Dose (Ag/rat) Survival (LD5o)
1 15 0.2 IgmNOV 10 10/10
2 IgmNOV 10 9/10
20 IgmNOV 10 9/10
2 5 2 IgmNOV 1 8/9
20 IgmNOV 1 9/9
200 IgmNOV 1 7/9
2 H46 0.05 6/9
20 H46 0 .05 3/9
3 6 0.3 IgmNOV 1 10/10
3.0 IgmNOV 1 10/10
33 .0 IgmNOV 1 9/9
0.3 H46 1 9/10
3.0 H46 1 10/10
33.0 H46 1 9/9648 HUMAN MONOCLONAL ANTI-GROUP B MENINGOCOCCAL ANTIBODY
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FIGURE 3.
￿
Anti-DNA ELISA of serum and purified IgMNOV in nanograms of nitrogen per
milliliter. NOV serum and five other sera containing monoclonal IgM proteins tested against
denatured (A) and native (B) DNA by ELISA. Serum dilutions have been converted to
nanograms of IgM present per milliliter, to adjust for the varyingamounts of macroglobulin
in each serum. Values represent mean of duplicate samples. (C) Anti-DNA ELISA of NOV
serum before and after absorption with meningococcal polysaccharide. A 1:10 dilution of
serum was added to 5.25 ug polysaccharide in a total volume of 200,1. The dilutions shown
are of thesupernatants with and without polysaccharide. (D) Purified IgMNOv with denatured
(de) DNA as the substrate. Values shownaremeans ofduplicates. Shaded circles indicate wells
coated with DNA; open circles indicate control wells without DNA.
and two had some specific activity against denatured DNA in the range of 10'-
104 ng/ml. None of these five sera had any specific activity against native DNA
at the dilutions tested.
Attempts to Establish B Cell Clones Making the Antibody.
￿
As a source of mono-
clonal IgM protein, we established several B cell lines using EBV infection, and
cloned them by limiting dilution. The supernatants from all of the B cell lines
were strongly positive against denatured DNA by ELISA. The anti-DNA ELISA
was used to screen supernatants, as it was at least 10-fold more sensitive than the
antimeningococcal assay. 4 of the 15 clones that grew at 10 cells/well had anti-
DNA activity, and one of the three clones that grew at an average of0.2 cells/well
were positive. Two of these five clones that showed the strongest anti-denatured
DNA activity were weakly positive by the antimeningococcus ELISA. Although
these clones maintained their specificity and were expanded over several weeks,
they subsequently stopped growing and with repeated feedings, the supernatants
lost anti-DNA activity . The phenotype of the B cell line NOV-1 was consistent
with EBV transformation rather than with that of fortuitously cultured plasma
cells. It was positive for B4, la, and A light chains by immunofluorescence, and
was negative for monocyte markers M1 and M2, the T cell marker, T3, and K
light chains.KABAT ET AL.
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Discussion
The antibody specificity of myeloma proteins and macroglobulins has been of
long-standing interest (21). In the course of screening sera from individuals with
monoclonal gammopathies, we have identified an IgM antibody with specificity
for poly-a(2 --* 8)-N-acetylneuraminic acid, which is the CPS of meningococcus
group B and E. coli KI . This antibody does not precipitate with poly-a(2 -~
9)NeuNAc nor with E. coli K92 CPS with alternating a(2 --3- 8) and a(2 -~
9)NeuNAc in quantitative precipitin studies. Absorption of serum with either
group B meningococcus or E. coli K1 CPS completely removes the monoclonal
peak . Its combining site is thus most likely directed toward an oligomer of a(2
--~- 8)NeuNAc. By quantitative precipitin studies, this antibody also reacts strongly
with denatured DNA and the polynucleotides poly(A), poly(I), and poly(G).
Poly(A) and poly(I) precipitate as well as poly-a(2 -~- 8)NeuNAc, and denatured
DNA reacts about one-third and poly(G) one-eighth as strongly (Fig. 1). With
other macroglobulins tested here and previously (22), concentrations ^-100 times
higher are required to show similar levels of binding with denatured DNA.
Minimal reactivity with native DNA was detectable both by direct and inhibition
ELISA, but not by quantitative precipitin tests.
The crossreactivity of this antibody with denatured and native DNA, and with
the polynucleotides poly(A), poly(I), and poly(G), was unanticipated. Theoreti-
cally, one might be concerned that the antibody might cause symptoms of SLE
if used in vivo,just as others (4, 5) have been concerned that antimeningococcal
vaccines might give rise to troublesome antibodies crossreacting with the gan-
gliosides GMs and GD3, which contain oligomers of poly-a(2 --*8)NeuNAc . This
particular antibody, however, does not crossreact with a mixture of gangliosides
or with purified GM3 (L . Freddo, and N. Latov, personal communication), and
in vivo at a concentration of 23 mg/ml, it has not caused signs or symptoms of
SLE.
Frosch et al. (23) have recently shown that, on injection of live meningococci,
autoimmune NZB mice can mount an IgG response to a(2 --3- 8)NeuNAc, in
contrast to normal BALB/c mice, which make only low levels of IgM. They have
exploited this finding to isolate an IgG2a mAb specific for a(2 --+ 8)NeuNAc
from an NZB mouse. It is interesting in the light of our findings of IgMNOV
reactivity with both a(2 ---> 8)NeuNAc and denatured DNA, that NZB mice, as
they mature, show increasingly high titers of IgM and IgG anti-DNA.
The activity of this antibody for denatured DNA also has relevance to recent
studies of anti-DNA mAbs isolated from patients with SLE. Numerous examples
of crossreactivity have been described among both humanand murine anti-DNA
antibodies, including those with various polynucleotides (24-26), phospholipids
(26), cell-surface polypeptides (27), and proteoglycans (28). These crossreactivi-
ties have been invoked in some cases to account for the protean serological and
clinical manifestations of SLE. Close scrutiny of anti-DNA antibodies has also
revealed some instances in which they appear to be closely related to antibacterial
antibodies (29). In one instance, a mutation giving rise to a single amino acid
difference in a mouse IgA myeloma heavy chain transformed an antiphosphoryl-
choline antibody into an antibody with specificity fordouble-stranded DNA (30).
In addition, the 16/6 idiotype, specific for an anti-DNA mAb, not only identifies650 HUMAN MONOCLONAL ANTI-GROUP B MENINGOCOCCAL ANTIBODY
tnany lupus sera (25), but also reacts with IgM macroglobulins (22), which are
specific for Klebsiella CPS with pyruvylated galactose (6). Part of the amino acid
sequence of the heavy and light chain variable regions of four 16/6-positive anti-
DNA antibodies has been determined (31), and the K light chains are homologous
to that of IgMWF^, which reacts with Klebsiella polysaccharide K30.
The molecular basis of these crossreactivities between lupus antibodies to DNA
and phospholipids, glycosaminoglycans, and cell surface proteins, as well as those
between the anti-Klebsiella macroglobulins and polynucleotides and their reac-
tivity with the 16/6 idiotype remains unknown. Others (26) have suggested that
phosphodiester groups with a given spacing might constitute a crossreacting
antigenic determinant between DNA and phospholipids. For bacterial polysac-
charides, a similar pattern of negative charges is recognized by closely related
antibodies. With IgM'ov, which recognizes DNA as well as poly-a(2 ->
8)NeuNAc, but not poly-a(2 --). 9)NeuNAc or alternating poly-a(2 ---> 8)a(2 --~
9)NeuNAc, the only structural feature to account for both reactivities would be
a similarity in the spatial distribution of charges between the carboxyl groups of
the poly-a(2 -), 8)NeuNAc and thephosphates of the denatured DNA or poly(A)
and poly(I). The charge distribution of the poly-a(2 --* 9)NeuNAc and the poly-
a(2 -+ 8)a(2 -~ 9)NeuNAc would be quite different, and so would support this
hypothesis. Indeed Lindon et al . (32) have shown substantial conformational
differences between poly-a(2 --> 8)NeuNAc (group B) and poly-a(2 -> 9)NeuNAc
(group C) by 3H nuclear magnetic resonance spectroscopy, indicating different
three-dimensional structures in solution. Heidelberger (33) has interpreted the
extensive crossreaction between types 8 and 19 pneumococcal polysaccharides
as due to the negatively charged phosphoryl-O-D-ManNAc of type 19 being able
to enter the type 8 site, which is specific for cellobiuronic acid with its carboxyl,
and vice versa. Thus, an important facet of crossreactivity to charged groups is
the apparent association of similarities and differences in charge distribution
being responsible for immunological crossreactions among what have been
generally considered diverse and structurally unrelated substances.
IgMN°v is protective in rats, and thus of potential use in serotherapy of
meningococcal group B and certain invasive E. coli infections. For reasons that
remain poorly understood, the poly-a(2 --+ 8)NeuNAc that makes up the capsular
polysaccharide of these organisms is weakly immunogenic in normal mice as well
as in humans (1, 3, 34). Group B meningococcal strains account for 70-80% of
endemic disease caused by meningococci in developed countries, of which at
least 10% are fatal, despite antibiotics (35). Deafness and other neurological
sequelae frequently result. K1 strains account for ^-80% of neonatal E. coli sepsis
and meningitis, and ^-11-25% of isolates from the blood of adult patients (36).
In the preantibiotic era, as early as 1900, horse antimemngococcal serum was
used in the treatment ofcerebrospinal meningitis, by injection into the subarach-
noid space, with surprisingly good results, especially considering the problems of
typing meningococci (37, 38). The antibody was almost certainly IgM, based on
subsequent studies of horse antisera to pneumococcal and other polysaccharides
(see 39). Moreno et al . (9, 40) have also shown that monoclonal IgMs specific for
meningococcal group B CPS are protective in mice, and Kim et al. (41) have
shown that murine mAb is effective in established E. coli K1 infections. Group BKABAT ET AL.
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antibody may be produced by injection of formalized meningococci in animals,
but whole meningococci are too toxic to permit their use in humans . There is
active investigation in developing a group B meningococcal vaccine (9, 40, 42),
which might be useful in populations such as military recruits. Even if such
efforts are successful, use of such a vaccine in groups not at high risk is not
necessarily warranted. In clustered outbreaks of disease in the general popula-
tion, however, group B-specific human antiserum as well as mAb might be
supplementary treatment for those infected .
In the attempt to produce human mAbs in vitro, we have immortalized B cells
from this patient and have shown that relevant antibody-producing cells are
present in these lines. Moreover, by limiting dilution, we have derived clones of
Bcellssecretingthis antibody. To date, however, these clones have been unstable
with respect to growth and antibody secretion. Nevertheless, that we have been
able to grow B cell clones secreting the myeloma protein from peripheral blood
with EBV is direct evidence of a circulating population of B cell precursors to
malignant plasma cells, and provides additional evidence to that derived by
studies with antiidiotypic antibodies that an expanded pool of such cells exists in
the peripheral blood of patients with plasma cell dyscrasias (43).
Summary
We have described an IgM antibody from a patient with macroglobulinemia
specifically reacting with poly-a(2 -~ 8)N-acetyl neuraminic acid (NeuNAc) the
capsular polysaccharide of two important human pathogens, group B meningo-
coccus and E. coli KI. This antibody has a narrowly defined specificity in its
interactions with polysaccharides, being unable to bind poly-a(2 -+ 9)NeuNAc
or alternating poly-a(2 --> 8)a(2 --> 9)NeuNAc. However, it shows interesting
crossreactivity with seemingly unrelated polynucleotides and denatured DNA,
supporting the hypothesis that charged groups with a given spacing may deter-
mine the specificity of antigen-antibody interactions on otherwise dissimilar
molecular structures. Despite the crossreactivity with denatured DNA and poly-
nucleotides, the antibody does not appear to have adverse effects in the patient.
The antibody protects newborn rats against E. coli K1 infection, as well as the
standard horse antiserum H46, and one would expect it to prove useful in
humans as an adjunct to antibiotic therapy in infections with group B meningo-
coccus and E. coli K1 . We have attempted to clone the antibody-producing cells
from peripheral blood, and have shown that the relevant cells are present and
can be cultured .
We thank Mr. Darryl J. Guinyard for typing the manuscript.
Receivedfor publication 15 April 1986.
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